ArticleNeurophotonics2025
Quantitative analysis of lipofuscin in neurodegenerative diseases using serial sectioning two-photon microscopy and fluorescence lifetime imaging microscopy.
Article in Neurophotonics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway.CNS neuroscience & therapeutics · 2026Article
- Metabolic reprogramming enhances oxidative stress resistance in differentiating cardiomyocytes.Scientific reports · 2026Article
- Lipofuscin accumulation in aging and neurodegeneration: a potential "timebomb" overlooked in Alzheimer's disease.Translational neurodegeneration · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lipofuscin, a cellular pigment that accumulates with age, serves as a significant marker of aging. Recently, studies have linked lipofuscin with neurodegenerative diseases, such as Alzheimer's disease (AD). Using an integrated serial sectioning optical coherence tomography (OCT) and two-photon microscopy (2PM) systems, we developed a method to examine the accumulation and distribution of lipofuscin in postmortem human brain samples. Lipofuscin was imaged with 2PM autofluorescence and quantitatively analyzed in specific structures revealed by OCT images. We involved samples from 15 people aged 60 to 90 years, including those with late-stage AD, chronic traumatized encephalopathy (CTE), and controls (NC). We developed a segmentation method for lipofuscin aggregates based on high-pass filtering and adaptive thresholding, achieving a Dice score of 61% using the integrated system at lower resolution when validated against high-resolution fluorescence lifetime imaging microscopy and phasor analysis. Quantitative metrics such as lipofuscin number density, area fraction, and radius were calculated, revealing distinct spatial distribution patterns across different brain regions and neurological conditions. AD cases exhibited a higher accumulation of lipofuscin in the gray matter sulcus regions compared with the controls, represented by the three metrics of density, area fraction, and size. The difference is particularly significant in number density. Furthermore, we discovered that lipofuscin forms layer structures in the cortical gray matter, which may be related to cell distribution in these regions. Further investigation of these areas revealed significant differences in CTE cases, especially in the infragranulary layer sulcus, compared with controls. In contrast to AD cases, the accumulation difference is significant in the sulcus of both the supergranular and infragranular layers compared with controls. These findings provide valuable information on the pathological role of lipofuscin in neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.